Can your genes predict chemo side effects?

NCT ID NCT06580106

Recruiting now Knowledge-focused Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This study is collecting genetic samples from 50 adults with newly diagnosed acute myeloid leukemia (AML) who are starting treatment with azacitidine and venetoclax. Researchers want to see if certain genetic variations are linked to severe side effects or how well the drugs work. The goal is to learn more, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: azacitidine and venetoclax
What this could lead to: If successful, this study could help doctors predict which patients are more likely to have severe side effects from azacitidine and venetoclax, leading to more personalized treatment plans.
What could go wrong: This is a small pilot study with only 50 participants, so findings may not apply to all patients. It is observational and does not test a new treatment, so it will not directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LEUKEMIA, MYELOID, ACUTE

Contacts and locations

Locations

Levine Cancer Institute
RECRUITING

Charlotte, North Carolina, 28204, United States
Wake Forest Baptist Comprehensive Cancer Center
RECRUITING

Winston-Salem, North Carolina, 27157, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.